Efficacy of Bifidobacterium breve NCC2950 against DSS-induced colitis is dependent on bacterial preparation and timing of administration
- 1 March 2014
- journal article
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 5 (1) , 79-88
Abstract
Probiotics have been proposed as a therapy for inflammatory bowel disease, but variations in strains, formulations, and protocols used in clinical trials have hindered the creation of guidelines for their use. Thus, preclinical insight into the mechanisms of specific probiotic strains and mode of administration would be useful to guide future clinical trial design. In this study, live, heat inactivated (HI), and spent culture medium preparations of the probiotic Bifidobacterium breve NCC2950 were administered to specific pathogen free C57BL/6 mice before or during colitis, as well as before colitis reactivation. Five days of 3.5% dextran sulphate sodium in drinking water was used to induce colitis. Pretreatment with live B. breve reduced disease severity, myeloperoxidase activity, microscopic damage, cytokine production, interleukin (IL)-12/IL-10 ratio, and lymphocyte infiltration in the colon. B. breve did not attenuate on-going colitis. After acute colitis, disease symptoms were normalised sooner with live and HI B. breve treatment; however, reactivation of colitis was not prevented. These findings indicate that the efficacy of a probiotic to modulate intestinal inflammation is dependent on the formulation as well as state of inflammation when administered. Overall, live B. breve was most efficacious in preventing acute colitis. Live and HI B. breve also promoted recovery from diarrhoea and colon bleeding after a bout of acute colitis.Keywords
This publication has 32 references indexed in Scilit:
- Probiotic Bifidobacterium breve Induces IL-10-Producing Tr1 Cells in the ColonPLOS Pathogens, 2012
- Probiotic modulation of dendritic cells co-cultured with intestinal epithelial cellsWorld Journal of Gastroenterology, 2012
- Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue ActivationPLOS ONE, 2011
- Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysisJournal of Gastroenterology, 2011
- In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effectsInternational Journal of Food Microbiology, 2010
- Mechanisms Involved in Alleviation of Intestinal Inflammation by Bifidobacterium Breve Soluble FactorsPLOS ONE, 2009
- Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trialsProceedings of the Nutrition Society, 2007
- The VSL# 3 Probiotic Mixture Modifies Microflora but Does Not Heal Chronic Dextran-Sodium Sulfate–Induced Colitis or Reinforce the Mucus Barrier in MiceThe Journal of Nutrition, 2005
- Probiotics Ameliorate Recurrent Th1-Mediated Murine Colitis by Inducing IL-10 and IL-10-Dependent TGF-β-Bearing Regulatory CellsThe Journal of Immunology, 2005
- Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokinesClinical and Experimental Immunology, 1998